Moreover, this process could also occur in early PD stages, preventing insulin and IGF-1 from binding to their receptors (Ir, IGF-1r), leading to increased GSK3β activity by disrupting the PI3K/Akt pathway. This evidence concerns the gene INSR and Parkinson disease.